Patent ID: 6566064
Filing Date: 2003-05-20
Classification: C12Q

Abstract:
A method for determining the relative sensitivity of an individual to treatment of osteoporosis with vitamin D, estrogen, and vitamin K2, comprising determining whether an individual's vitamin D receptor genotype is B(+) or B(âˆ’), where B(+) represents the genotypes BB and Bb and B(âˆ’) represents the genotype bb, where B is a vitamin D receptor allele that is not cleaved with Bsm I in an intron region between exon 8 and exon 9 and b is a vitamin D receptor allele that is cleaved with Bsm I in an intron region between exon 8 and exon 9, determining whether the individual's estrogen receptor genotype is X(+) or X(âˆ’), where X(+) represents the genotypes XX and Xx and X(âˆ’) represents the genotype xx, where X is an estrogen receptor allele that is not cleaved with Xba in an intron region between exon 1 and exon 2 and x is an estrogen receptor allele that is cleaved with Xba in an intron region between exon 1 and exon 2, and determining whether the individual's apolipoprotein E genotype is 3(+), 3(âˆ’), 4(+), or 4(âˆ’), where 3(+) represents an apolipoprotein E 3/3 type, and 3(âˆ’) indicates an apolipoprotein E genotype other than apolipoprotein E 3/3 type, and 4 represents an apolipoprotein E4 allele, and (+) and (âˆ’) indicate the presence and absence, respectively, of the allele; wherein the combination of said individual's vitamin D receptor genotype, estrogen receptor genotype, and apolipoprotein E genotype is associated with the individual's relative sensitivity to vitamin D, estrogen and vitamin K2.